Academic Journal
Beyond histocompatibility: human leukocyte antigen as a cross-disciplinary platform for immune recognition and clinical decision-making.
| Τίτλος: | Beyond histocompatibility: human leukocyte antigen as a cross-disciplinary platform for immune recognition and clinical decision-making. |
|---|---|
| Συγγραφείς: | Mandal S; Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom.; NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom., Deb J; Transfusion Medicine & Blood Centre, Apollo Excelcare Hospital, Guwahati, India., Mohan AK; Transfusion Medicine, All India Institute of Medical Sciences, Bibinagar, India., Sil S; Transfusion Medicine, Rajiv Gandhi Super Speciality Hospital, New Delhi, India., Maji M; Hull York Medical School, University of Hull, Hull, United Kingdom.; Haematology, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom., Hasan S; Queen's Centre for Oncology, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom., Ashraf FH; HPB Medicine and Gastroenterology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom., Dhali A; Division of Cancer, Imperial College London, London, United Kingdom.; Academic Gastroenterology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom. |
| Πηγή: | Frontiers in immunology [Front Immunol] 2026 Sep 08; Vol. 17, pp. 1931212. Date of Electronic Publication: 2026 Sep 08 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Ιατρικοί όροι (MeSH): | HLA Antigens*/immunology , HLA Antigens*/genetics , Histocompatibility*/immunology , Clinical Decision-Making*, Histocompatibility Testing/methods ; Graft vs Host Disease/immunology ; Humans ; Hematopoietic Stem Cell Transplantation ; Organ Transplantation ; Female |
| Περίληψη: | Human leukocyte antigen (HLA) molecules mediate peptide presentation and shape immune recognition, with clinical relevance well beyond donor-recipient matching. This review describes how HLA variation and anti-HLA immunity affect transfusion medicine, autoimmune and infectious diseases, pharmacogenomics, cancer, pregnancy, solid organ transplantation and haematopoietic stem cell transplantation (HSCT). It outlines HLA nomenclature and testing, including sequence-based typing, single-antigen bead assays, virtual crossmatching and molecular mismatch analysis, and considers how population-specific allele and haplotype frequencies affect interpretation. An HLA result must be interpreted in clinical context, including exposure history, donor specificity, antibody strength, assay characteristics, organ type, molecular mismatch, HLA evolutionary divergence, immunosuppression and ancestry. In transfusion medicine, recipient alloimmunisation can cause platelet refractoriness and complicate future transplantation, whereas donor antibodies contribute to transfusion-related acute lung injury. Transfusion-associated graft-versus-host disease is a different cellular complication. In autoimmunity, type 1 diabetes and systemic lupus erythematosus show how HLA class II variation can influence peptide selection, immune tolerance and autoantibody profiles, although most associations are not diagnostic alone. Pharmacogenomic testing has clearer clinical value for selected drugs, including abacavir, carbamazepine and allopurinol. In cancer, loss of classical HLA expression and non-classical HLA-E and HLA-G pathways contribute to immune escape and are being explored as therapeutic targets. In transplantation, HLA assessment increasingly combines donor-specific antibodies, crossmatch results, molecular mismatch and organ-specific risk. Eplet, amino-acid and predicted indirect T-cell epitope mismatch can support risk assessment at population level, but no single score should determine organ allocation or immunosuppression. HSCT differs because the graft transfers a donor immune system, creating competing risks of graft failure, graft-versus-host disease and relapse. Clinical implementation requires reliable assays, validated clinical associations, evidence of patient benefit, multi-ancestry validation, consistent reporting and equitable access. We distinguish established clinical practice from developing risk-stratification methods and early mechanistic findings. (Copyright © 2026 Mandal, Deb, Mohan, Sil, Maji, Hasan, Ashraf and Dhali.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor GKP declared a past co-authorship/collaboration with the author SS. |
| References: | Cancers (Basel). 2026 May 25;18(11):. (PMID: 42279307) Hum Immunol. 2017 Jul - Aug;78(7-8):471-480. (PMID: 28576578) Transfusion. 2018 Jun;58(6):1536-1539. (PMID: 29516495) Blood. 2000 Dec 15;96(13):4011-9. (PMID: 11110668) Clin Pharmacol Ther. 2018 Apr;103(4):574-581. (PMID: 29392710) Vox Sang. 2022 Nov;117(11):1251-1261. (PMID: 36102140) Transplantation. 2013 Jan 15;95(1):19-47. (PMID: 23238534) Blood Rev. 2023 May;59:101038. (PMID: 36581513) Clin Pharmacol Ther. 2016 Jan;99(1):36-7. (PMID: 26094938) Blood Rev. 2023 Nov;62:101135. (PMID: 37805287) Front Immunol. 2021 Mar 10;11:623276. (PMID: 33776988) Immunogenetics. 2020 Feb;72(1-2):119-129. (PMID: 31741009) Blood. 2007 Dec 15;110(13):4576-83. (PMID: 17785583) Immunol Rev. 2013 Jul;254(1):245-64. (PMID: 23772624) Am J Transplant. 2026 May;26(5):1048-1069. (PMID: 41519473) Am J Transplant. 2011 Dec;11(12):2737-46. (PMID: 21906255) Transfusion. 2023 Jun;63(6):1141-1149. (PMID: 37038316) Transplantation. 2009 Oct 27;88(8):1019-24. (PMID: 19855248) N Engl J Med. 1986 Jul 3;315(1):29-35. (PMID: 3520323) Methods Mol Biol. 2013;1034:41-70. (PMID: 23775730) Sci Rep. 2025 Jul 2;15(1):23667. (PMID: 40603473) J Heart Lung Transplant. 2017 May;36(5):540-545. (PMID: 27916323) Cell. 2018 Dec 13;175(7):1731-1743.e13. (PMID: 30503213) PLoS One. 2015 May 27;10(5):e0127153. (PMID: 26018555) J Heart Lung Transplant. 2010 Aug;29(8):914-56. (PMID: 20643330) N Engl J Med. 2008 Feb 7;358(6):568-79. (PMID: 18256392) Am J Transplant. 2012 Feb;12(2):388-99. (PMID: 22081892) Transpl Int. 2025 Aug 13;38:14716. (PMID: 40881320) Nucleic Acids Res. 2026 Jan 6;54(D1):D1152-D1158. (PMID: 41251166) J Immunother Cancer. 2024 Oct 31;12(10):. (PMID: 39486805) Transplant Proc. 2023 Mar;55(2):303-308. (PMID: 36890054) HLA. 2026 Mar;107(3):e70595. (PMID: 41742599) Front Immunol. 2021 Oct 29;12:744324. (PMID: 34777357) Blood. 2015 Jul 16;126(3):406-14. (PMID: 25931584) Nature. 1991 Aug 15;352(6336):595-600. (PMID: 1865923) Transfusion. 2019 Mar;59(3):1118-1124. (PMID: 30548476) PLoS One. 2025 Oct 27;20(10):e0334851. (PMID: 41144540) Blood. 1998 Nov 15;92(10):3515-20. (PMID: 9808542) Transfusion. 2014 Aug;54(8):1971-80. (PMID: 24654685) Immunity. 2011 Jul 22;35(1):23-33. (PMID: 21683626) Transpl Immunol. 2022 Dec;75:101680. (PMID: 35908630) Front Immunol. 2022 Oct 28;13:1005601. (PMID: 36389845) Nat Med. 2019 Nov;25(11):1715-1720. (PMID: 31700181) Front Immunol. 2021 Jun 30;12:698677. (PMID: 34276691) Transfus Apher Sci. 2023 Dec;62(6):103789. (PMID: 37673757) N Engl J Med. 2000 Sep 7;343(10):702-9. (PMID: 10974135) Front Lupus. 2024;2:. (PMID: 39624492) Eur Respir J. 2017 Nov 16;50(5):. (PMID: 29146602) Front Immunol. 2024 Sep 12;15:1457213. (PMID: 39328411) Transfusion. 2019 Jul;59(7):2465-2476. (PMID: 30993745) J Am Soc Nephrol. 2020 Sep;31(9):2193-2204. (PMID: 32764139) Am J Transplant. 2012 Jun;12(6):1504-10. (PMID: 22420671) Am J Clin Oncol. 2026 Jul 3;:. (PMID: 42418277) Eur J Immunol. 2012 Jan;42(1):17-26. (PMID: 22125159) Front Immunol. 2016 Dec 09;7:570. (PMID: 28018342) Blood. 2012 Jun 7;119(23):5563-74. (PMID: 22490333) Front Immunol. 2025 Feb 11;16:1548934. (PMID: 40007544) Front Immunol. 2024 Aug 19;15:1440911. (PMID: 39229273) Bone Marrow Transplant. 2026 Aug;61(8):1015-1023. (PMID: 42230962) Blood. 2012 Feb 16;119(7):1757-67. (PMID: 22117051) N Engl J Med. 2011 Mar 24;364(12):1126-33. (PMID: 21428768) N Engl J Med. 1997 Dec 25;337(26):1861-9. (PMID: 9417523) Transfus Med Hemother. 2018 Oct;45(5):311-316. (PMID: 31049048) Transplant Cell Ther. 2026 Jan;32(1):74.e1-74.e14. (PMID: 41043776) J Leukoc Biol. 2011 Oct;90(4):703-16. (PMID: 21873457) Heliyon. 2024 Jul 22;10(15):e34977. (PMID: 39144953) Lancet Oncol. 2012 Apr;13(4):366-74. (PMID: 22340965) Hum Immunol. 2024 Jan;85(1):110734. (PMID: 38030522) Front Genet. 2024 Aug 28;15:1447141. (PMID: 39262421) Methods Mol Biol. 2006;333:157-74. (PMID: 16790851) Transpl Immunol. 2023 Apr;77:101783. (PMID: 36608831) Biol Blood Marrow Transplant. 2019 Jul;25(7):1395-1406. (PMID: 30826463) Scand J Immunol. 2015 Oct;82(4):283-306. (PMID: 26099424) Nephrol Dial Transplant. 2013 Nov;28(11):2908-18. (PMID: 24009295) J Clin Pathol. 2010 May;63(5):387-90. (PMID: 20418230) Am J Transplant. 2025 Jun;25(6):1226-1234. (PMID: 39631566) Kidney Int. 2021 Nov;100(5):1012-1022. (PMID: 34246656) Nat Rev Nephrol. 2018 Sep;14(9):558-570. (PMID: 29985463) Blood. 2010 Apr 1;115(13):2704-8. (PMID: 20089963) Clin Pharmacol Ther. 2014 May;95(5):499-500. (PMID: 24561393) Ann Intern Med. 2021 Oct;174(10):1385-1394. (PMID: 34424731) Kidney Int Rep. 2022 Mar 15;7(6):1179-1188. (PMID: 35685330) Transplant Proc. 2017 Apr;49(3):425-429. (PMID: 28340805) J Allergy Clin Immunol. 2019 Jul;144(1):183-192. (PMID: 30776417) Front Immunol. 2025 Feb 25;16:1528177. (PMID: 40070842) Lancet Haematol. 2020 Jan;7(1):e50-e60. (PMID: 31669248) Front Immunol. 2023 Feb 09;14:1125367. (PMID: 36845153) Front Immunol. 2021 May 04;12:661135. (PMID: 34017337) Tissue Antigens. 2012 Jul;80(1):1-11. (PMID: 22651253) iScience. 2023 May 19;26(5):106763. (PMID: 37168557) Nat Commun. 2014 Dec 23;5:5902. (PMID: 25533202) Front Immunol. 2021 Mar 09;12:636568. (PMID: 33767702) |
| Contributed Indexing: | Keywords: HLA; HLA evolutionary divergence; HLA-E; HLA-G; cancer immunology; donor-specific antibodies; eplet matching; haematopoietic stem cell transplantation |
| Substance Nomenclature: | 0 (HLA Antigens) |
| Entry Date(s): | Date Created: 20260923 Date Completed: 20260923 Latest Revision: 20260924 |
| Update Code: | 20260924 |
| PubMed Central ID: | PMC13595195 |
| DOI: | 10.3389/fimmu.2026.1931212 |
| PMID: | 42774728 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1931212 |